BACKGROUND: S-Adenosylmethionine (AdoMet) is a major methyl donor for transmethylation reactions and propylamine donor for the biosynthesis of polyamines in biological systems, and therefore may play a role in lung cancer development. We hypothesized that AdoMet levels were elevated in patients with lung cancer and may prove useful as a biomarker for early lung cancer. METHODS: High-performance liquid chromatography was used to analyze plasma AdoMet levels in triplicate samples from 68 patients. This included 13 patients with lung cancer, 33 smokers with benign lung disease, and 22 healthy nonsmokers. The three groups of subjects were compared with respect to the distribution of demographic and disease characteristics and AdoMet levels. Distributions were examined using summary statistics and box plots, and nonparametric analysis of variance procedures. RESULTS: Serum AdoMet levels were elevated in patients with lung cancer as compared to smokers with benign lung disorders and healthy nonsmokers. There were no significant correlations between AdoMet levels and tumor cell types, nodule size, or other demographic variables. CONCLUSIONS: Our data demonstrate that plasma levels of AdoMet are significantly elevated in patients with lung cancer. Plasma AdoMet levels may prove to be a useful tool for the diagnosis of early lung cancer, in combination with chest CT. Registered at: clinicaltrials.gov (NCT00301119).
BACKGROUND:S-Adenosylmethionine (AdoMet) is a major methyl donor for transmethylation reactions and propylaminedonor for the biosynthesis of polyamines in biological systems, and therefore may play a role in lung cancer development. We hypothesized that AdoMet levels were elevated in patients with lung cancer and may prove useful as a biomarker for early lung cancer. METHODS: High-performance liquid chromatography was used to analyze plasma AdoMet levels in triplicate samples from 68 patients. This included 13 patients with lung cancer, 33 smokers with benign lung disease, and 22 healthy nonsmokers. The three groups of subjects were compared with respect to the distribution of demographic and disease characteristics and AdoMet levels. Distributions were examined using summary statistics and box plots, and nonparametric analysis of variance procedures. RESULTS: Serum AdoMet levels were elevated in patients with lung cancer as compared to smokers with benign lung disorders and healthy nonsmokers. There were no significant correlations between AdoMet levels and tumor cell types, nodule size, or other demographic variables. CONCLUSIONS: Our data demonstrate that plasma levels of AdoMet are significantly elevated in patients with lung cancer. Plasma AdoMet levels may prove to be a useful tool for the diagnosis of early lung cancer, in combination with chest CT. Registered at: clinicaltrials.gov (NCT00301119).
Authors: Steven A Belinsky; Donna M Klinge; Joseph D Dekker; Mitzi W Smith; Theresa J Bocklage; Frank D Gilliland; Richard E Crowell; Daniel D Karp; Christine A Stidley; Maria A Picchi Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531
Authors: C I Henschke; D I McCauley; D F Yankelevitz; D P Naidich; G McGuinness; O S Miettinen; D M Libby; M W Pasmantier; J Koizumi; N K Altorki; J P Smith Journal: Lancet Date: 1999-07-10 Impact factor: 79.321
Authors: Mihalis I Panayiotidis; Sally P Stabler; Robert H Allen; Aftab Ahmad; Carl W White Journal: Chem Biol Interact Date: 2004-01-15 Impact factor: 5.192
Authors: A Kamb; N A Gruis; J Weaver-Feldhaus; Q Liu; K Harshman; S V Tavtigian; E Stockert; R S Day; B E Johnson; M H Skolnick Journal: Science Date: 1994-04-15 Impact factor: 47.728
Authors: Kellyn M Hoffert; Kathryn S P Higginbotham; Justin T Gibson; Stuart Oehrle; Erin D Strome Journal: Genetics Date: 2019-07-18 Impact factor: 4.562
Authors: Mohamed Hassanein; J Clay Callison; Carol Callaway-Lane; Melinda C Aldrich; Eric L Grogan; Pierre P Massion Journal: Cancer Prev Res (Phila) Date: 2012-06-11
Authors: Rachel M Ostroff; William L Bigbee; Wilbur Franklin; Larry Gold; Mike Mehan; York E Miller; Harvey I Pass; William N Rom; Jill M Siegfried; Alex Stewart; Jeffrey J Walker; Joel L Weissfeld; Stephen Williams; Dom Zichi; Edward N Brody Journal: PLoS One Date: 2010-12-07 Impact factor: 3.240